{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:20:50Z","timestamp":1785334850453,"version":"3.55.0"},"reference-count":33,"publisher":"Portland Press Ltd.","issue":"6","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":110,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We identified patients diagnosed with malignant astrocytoma (MA) as the first of two or more primary malignancies between 1973 and 2015 from Surveillance, Epidemiology and End Results (SEER) database. Multiple primaries-standardized incidence ratio (MP-SIR) was calculated to quantitate the risk of second primary malignancy (SPM). We further identified the risk factors of developing SPM and factors affecting overall survival (OS) in MA patients with SPM. Our results revealed that overall risk of SPM among MA patients was significantly higher than that in general population (SIR: 1.09, 95% confidence interval (CI): 1\u20131.18, P&amp;lt;0.05). Specific sites where the risk of SPM increased included salivary gland, bone and joints, soft tissue including heart, brain, cranial nerves other nervous system, thyroid, acute non-lymphocytic leukemia and acute myeloid leukemia. Overall risk of SPM in patients aged \u226429 and 30\u201359 years significantly increased (4.34- and 1.41-fold respectively). Whereas patients aged \u226560 years had a significantly decreased risk of SPM. Patients in the group of latency at 36\u201359, 60\u2013119 and \u2265120 months carried significantly increased overall risk of SPM. Multivariate analysis revealed that age, race, marital status, WHO grade, differentiated grade of cancer tissues, latency was independent predictor of OS in MA patients with SPM, which were all selected into the nomogram. The calibration curve for probability of survival showed good agreement between prediction by nomogram and actual observation. In conclusion, MA survivors should be advised of their increased risk for developing certain cancers in their lifetime. Our study had clinical implications for the surveillance of MA survivors at risk of developing SPM.<\/jats:p>","DOI":"10.1042\/bsr20181968","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:45:57Z","timestamp":1559072757000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study"],"prefix":"10.1042","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0610-6282","authenticated-orcid":false,"given":"Wenming","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Traditional Chinese Medicine, Beijing Tian Tan Hospital, Capital Medical University, 119 South 4th Ring West Road, Beijing 100070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2019,6,14]]},"reference":[{"key":"2021111619392443400_B1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3322\/caac.21183","article-title":"Advancing survivorship care through the National Cancer Survivorship Resource Center: developing American Cancer Society guidelines for primary care providers","volume":"63","author":"Cowens-Alvarado","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"2021111619392443400_B2","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1002\/cncr.28769","article-title":"Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study","volume":"120","author":"Davis","year":"2014","journal-title":"Cancer"},{"key":"2021111619392443400_B3","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/sj.bjc.6601319","article-title":"Second primary malignancies in thyroid cancer patients","volume":"89","author":"Rubino","year":"2003","journal-title":"Br. J. Cancer"},{"key":"2021111619392443400_B4","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1038\/sj.bjc.6603172","article-title":"Multiple primary tumours in women following breast cancer, 1973-2000","volume":"94","author":"Raymond","year":"2006","journal-title":"Br. J. Cancer"},{"key":"2021111619392443400_B5","first-page":"3855","article-title":"Second primary malignancies in adult acute myeloid leukemia - a US population-based study","volume":"34","author":"Ghimire","year":"2014","journal-title":"Anticancer Res."},{"key":"2021111619392443400_B6","article-title":"Neoplasms of the central nervous system","volume-title":"Atlas of Diagnostic Oncology","author":"Maher","year":"2003","edition":"3rd"},{"key":"2021111619392443400_B7","article-title":"CBTRUS Statistical Report. Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008, Central Brain Tumor Registry of the United States, 2000-2004","author":"CBTRUS","year":"2008"},{"key":"2021111619392443400_B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/neuonc\/not151","article-title":"Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro Oncol."},{"key":"2021111619392443400_B9","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1101\/gad.1596707","article-title":"Malignant astrocytic glioma: genetics, biology, and paths to treatment","volume":"21","author":"Furnari","year":"2007","journal-title":"Genes Dev"},{"key":"2021111619392443400_B10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1053\/j.seminoncol.2014.06.013","article-title":"Supratentorial low-grade diffuse astrocytoma: medical management","volume":"41","author":"Ajlan","year":"2014","journal-title":"Semin Oncol"},{"key":"2021111619392443400_B11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ncl.2018.04.005","article-title":"Grade II and III oligodendroglioma and astrocytoma","volume":"36","author":"van den Bent","year":"2018","journal-title":"Neurol. Clin."},{"key":"2021111619392443400_B12","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1200\/JCO.2017.72.6737","article-title":"Diffuse infiltrating oligodendroglioma and astrocytoma","volume":"35","author":"van den Bent","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"2021111619392443400_B13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2021111619392443400_B14","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/neuonc\/nos153","article-title":"A populationbased study on the effect of temozolomide in the treatment of glioblastoma multiforme","volume":"14","author":"R\u00f8nning","year":"2012","journal-title":"Neuro Oncol."},{"key":"2021111619392443400_B15","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"2021111619392443400_B16","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA"},{"key":"2021111619392443400_B17","volume-title":"SEER Program Code Manual","author":"Fritz","year":"1998","edition":"3rd"},{"key":"2021111619392443400_B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"2021111619392443400_B19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1634\/theoncologist.11-2-152","article-title":"Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents","volume":"11","author":"Reardon","year":"2006","journal-title":"Oncologist"},{"key":"2021111619392443400_B20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.critrevonc.2007.03.003","article-title":"Anaplastic astrocytoma in adults","volume":"63","author":"Stupp","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2021111619392443400_B21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3109\/02841869709001300","article-title":"Multiple primary malignant tumours in a national cancer registry","volume":"36","author":"Fr\u00f6din","year":"1997","journal-title":"Acta Oncol."},{"key":"2021111619392443400_B22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jocn.2013.07.032","article-title":"Temozolomide-related acute lymphoblastic leukemia with translocation (4;11) (q21;q23) in a glioblastoma patient","volume":"21","author":"Chou","year":"2014","journal-title":"J. Clin. Neurosci."},{"key":"2021111619392443400_B23","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.ijrobp.2018.07.2004","article-title":"Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients","volume":"102","author":"Berberich","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2021111619392443400_B24","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.humpath.2012.05.003","article-title":"IDH mutations in acute myeloid leukemia","volume":"43","author":"Rakheja","year":"2012","journal-title":"Hum. Pathol."},{"key":"2021111619392443400_B25","doi-asserted-by":"publisher","first-page":"S607","DOI":"10.4103\/2152-7806.189731","article-title":"Ollier disease with anaplastic astrocytoma: a review of the literature and a unique case","volume":"7","author":"Gajavelli","year":"2016","journal-title":"Surg. Neurol. Int."},{"key":"2021111619392443400_B26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3892\/or.2017.5655","article-title":"HIF-1\u03b1 inhibits IDH-1 expression in osteosarcoma","volume":"38","author":"Liu","year":"2017","journal-title":"Oncol. Rep."},{"key":"2021111619392443400_B27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov."},{"key":"2021111619392443400_B28","doi-asserted-by":"crossref","article-title":"PDGFRa amplification in multiple skin lesions of undifferentiated pleomorphic sarcoma: a clue for intimal sarcoma metastases","author":"Osio","DOI":"10.1111\/cup.12907"},{"key":"2021111619392443400_B29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"2021111619392443400_B30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3%3c366::AID-IJC9%3e3.0.CO;2-0","article-title":"Familial aggregation of astrocytoma in northern Sweden: an epidemiological cohort study","volume":"81","author":"Malmer","year":"1999","journal-title":"Int. J. Cancer"},{"key":"2021111619392443400_B31","doi-asserted-by":"crossref","first-page":"64954","DOI":"10.18632\/oncotarget.11066","article-title":"Marital status and survival in patients with primary liver cancer","volume":"8","author":"He","year":"2016","journal-title":"Oncotarget"},{"key":"2021111619392443400_B32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000353135","article-title":"Analysis of risk factors and survival in pediatric high-grade spinal cord astrocytoma: a population-based study","volume":"48","author":"Lam","year":"2012","journal-title":"Pediatr. Neurosurg."},{"key":"2021111619392443400_B33","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.wneu.2017.03.140","article-title":"Effect of gross total resection in World Health Organization Grade II astrocytomas: SEER-based survival analysis","volume":"103","author":"Schupper","year":"2017","journal-title":"World Neurosurg."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181968\/845678\/bsr-2018-1968.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181968\/845678\/bsr-2018-1968.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:27:02Z","timestamp":1637094422000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/39\/6\/BSR20181968\/219219\/Increased-incidence-of-second-primary-malignancy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,28]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20181968","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,6]]},"article-number":"BSR20181968"}}